Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model

Toxins

Volumn 4, Issue 11, 2012, Pages 1058-1081

  Miguel, Antonio ^a   Herrero, María José ^a,b   Sendra, Luis ^a   Botella, Rafael ^c   Algás, Rosa ^d   Sánchez, Maria ^a   Aliño, Salvador F ^a,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

B7.2; Cancer vaccines; Gene therapy; GM CSF; Non viral

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; MELANOMA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER SIZE; CANCER SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IRRADIATION; MELANOMA B16; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD86; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN G; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TRANSFECTION;

ANIMALIA; MURINAE; MUS;

EID: 84870573614     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4111058     Document Type: Article

References (68)

1. Kim, S.; Carew, J.F.; Kooby, D.A.; Shields, J.; Entwisle, C.; Patel, S.; Shah, J.P.; Fong, Y. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer. Cancer Gene Ther. 2000, 7, 1279-1285.
2. Veelken, H.; Mackensen, A.; Lahn, M.; Kohler, G.; Becker, D.; Franke, B.; Brennscheidt, U.; Kulmburg, P.; Rosenthal, F.M.; Keller, H.; et al. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 1997, 70, 269-277.
3. Palmer, K.; Moore, J.; Everard, M.; Harris, J.D.; Rodgers, S.; Rees, R.C.; Murray, A.K.; Mascari, R.; Kirkwood, J.; Riches, P.G.; et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 1999, 10, 1261-1268.
4. Wittig, B.; Marten, A.; Dorbic, T.; Weineck, S.; Min, H.; Niemitz, S.; Trojaneck, B.; Flieger, D.; Kruopis, S.; Albers, A.; et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial. Hum. Gene Ther. 2001, 12, 267-278.
5. Moller, P.; Sun, Y.; Dorbic, T.; Alijagic, S.; Makki, A.; Jurgovsky, K.; Schroff, M.; Henz, B.M.; Wittig, B.; Schadendorf, D. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br. J. Cancer 1998, 77, 1907-1916.
6. Maio, M.; Fonsatti, E.; Lamaj, E.; Altomonte, M.; Cattarossi, I.; Santantonio, C.; Melani, C.; Belli, F.; Arienti, F.; Colombo, M.P.; et al. Vaccination of stage IV patients with allogeneic IL-4-or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. 2002, 51, 9-14.
7. Arienti, F.; Belli, F.; Napolitano, F.; Sule-Suso, J.; Mazzocchi, A.; Gallino, G.F.; Cattelan, A.; Santantonio, C.; Rivoltini, L.; Melani, C.; et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 1999, 10, 2907-2916.
8. Bowman, L.C.; Grossmann, M.; Rill, D.; Brown, M.; Zhong, W.Y.; Alexander, B.; Leimig, T.; Coustan-Smith, E.; Campana, D.; Jenkins, J.; et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther. 1998, 9, 1303-1311.
9. Belli, F.; Arienti, F.; Sule-Suso, J.; Clemente, C.; Mascheroni, L.; Cattelan, A.; Santantonio, C.; Gallino, G.F.; Melani, C.; Rao, S.; et al. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 1997, 44, 197-203.
10. Olivares, J.; Kumar, P.; Yu, Y.; Maples, P.B.; Senzer, N.; Bedell, C.; Barve, M.; Tong, A.; Pappen, B.O.; Kuhn, J.; et al. Phase I trial of TGF-β2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin. Cancer Res. 2011, 1, 183-192.
11. Agarwalla, P.; Barnard, Z.; Fecci, P.; Dranoff, G.; Curry, W.T., Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 2012, 35, 385-389.
12. Jaffee, E.M.; Abrams, R.; Cameron, J.; Donehower, R.; Duerr, M.; Gossett, J.; Greten, T.F.; Grochow, L.; Hruban, R.; Kern, S.; Lillemoe, K.D.; O'Reilly, S.; et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum. Gene Ther. 1998, 9, 1951-1971.
13. Ojima, T.; Iwahashi, M.; Nakamura, M.; Matsuda, K.; Naka, T.; Nakamori, M.; Ueda, K.; Ishida, K.; Yamaue, H. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int. J. Oncol. 2006, 289, 47-53.
14. Dranoff, G.; Jaffee, E.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Jackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R.C. Vaccination with irradiated tumor cells engineered to secrete granulocyte-Macrophage colony-stimulating factor (GM-CSF) stimulates potent, specific, and long-lasting antitumor immunity in multiple murine tumor model systems, including malignant melanoma. Proc. Natl. Acad. Sci. USA 1993, 90, 3539-3543.
15. Parmiani, G.; Castelli, C.; Pilla, L.; Santinami, M.; Colombo, M.P.; Rivoltini, L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 2007, 18, 226-232.
16. Curiel-Lewandrowski, C.; Mahnke, K.; Labeur, M.; Roters, B.; Schmidt, W.; Granstein, R.D.; Luger, T.A.; Schwarz, T.; Grabbe, S. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J. Immunol. 1999, 163, 174-183.
17. Dunussi-Joannopoulos, K.; Dranoff, G.; Weinstein, H.J.; Ferrara, J.L.; Bierer, B.E.; Croop, J.M. Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998, 91, 222-230.
18. Soiffer, R.; Hodi, F.S.; Haluska, F.; Jung, K.; Gillessen, S.; Singer, S.; Tanabe, K.; Duda, R.; Mentzer, S.; Jaklitsch, M.; et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 2003, 21, 3343-3350.
19. Nemunaitis, J.; Sterman, D.; Jablons, D.; Smith, J.W.; Fox, B.; Maples, P.; Hamilton, S.; Borellini, F.; Lin, A.; Morali, S.; et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. 2004, 96, 326-331.
20. Salgia, R.; Lynch, T.; Skarin, A.; Lucca, J.; Lynch, C.; Jung, K.; Hodi, F.S.; Jaklitsch, M.; Mentzer, S.; Swanson, S.; et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 2003, 21, 624-630.
21. Soiffer, R.; Lynch, T.; Mihm, M.; Jung, K.; Rhuda, C.; Schmollinger, J.C.; Hodi, F.S.; Liebster, L.; Lam, P.; Mentzer, S.; et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 1998, 95, 13141-13146.
22. Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba, W.J.; Dula, E.; Centeno, A.S.; Nelson, W.G.; Ando, D.; Howard, C.; Borellini, F.; et al. Granulocyte macrophage colony-stimulating factor-Secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13, 3883-3891.
23. Jaffee, E.M.; Hruban, R.H.; Biedrzycki, B.; Laheru, D.; Schepers, K.; Sauter, P.R.; Goemann, M.; Coleman, J.; Grochow, L.; Donehower, R.C.; et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-Secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J. Clin. Oncol. 2001, 19, 145-156.
24. Borrello, I.; Pardoll, D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev. 2002, 13, 185-193.
25. Moret-Tatay, I.; Diaz, J.; Marco, F.M.; Crespo, A.; Aliño, S.F. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene Ther. 2003, 10, 887-897.
26. Moret-Tatay, I.; Sanmartín, I.; Marco, F.M.; Díaz, J.; Aliño, S.F. Nonviral therapeutic cell vaccine mediates potent antitumor effects. Vaccine 2006, 24, 3937-3945.
27. Herrero, M.J.; Botella, R.; Dasí, F.; Algás, R.; Sánchez, M.; Aliño, S.F. Antigens and cytokine genes in antitumor vaccines: The importance of the temporal delivery sequence in antitumor signals. Ann. N. Y. Acad. Sci. 2006, 1091, 412-424.
28. Zhang, X.; Shi, X.; Li, J.; Hu, Z.; Zhou, D.; Gao, J.; Tan, W. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J. Urol. 2012, 187, 1071-1079.
29. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991, 9, 271-296.
30. Chong, H.; Todryk, S.; Hutchinson, G.; Hart, I.R.; Vile, R.G. Tumor cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumor response and may generate systemic protective immunity. Gene Ther. 1998, 5, 223-232.
31. Kim, K.Y.; Kang, M.A.; Nam, M.J. Enhancement of natural killer cell-mediated cytotoxicity by coexpression of GM-CSF/B70 in hepatoma. Cancer Lett. 2001, 166, 33-40.
32. Mukherjee, S.; Nelson, D.; Loh, S.; van Bruggen, I.; Palmer, L.J.; Leong, C.; Garlepp, M.J.; Robinson, B.W. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther. 2001, 8, 580-588.
33. Parney, I.F.; Farr-Jones, M.A.; Kane, K.; Chang, L.J.; Petruk, K.C. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF and IL-12. Can. J. Neurol. Sci. 2002, 29, 267-275.
34. Parney, I.F.; Chang, L.J.; Farr-Jones, M.A.; Hao, C.; Smylie, M.; Petruk, K.C. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J. Neurooncol. 2006, 78, 71-80.
35. Zajac, P.; Oertli, D.; Marti, W.; Adamina, M.; Bolli, M.; Guller, U.; Noppen, C.; Padovan, E.; Schultz-Thater, E.; Heberer, M.; et al. Phase I/II Clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther. 2003, 14, 1497-1510.
36. Pizzoferrato, E. B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma. Int. J. Cancer 2004, 110, 61-69.
37. Shi, F.S.; Weber, S.; Gan, J.; Rakhmilevich, A.L.; Mahvi, D.M. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther. 1999, 6, 81-88.
38. Herrero, M.J.; Botella, R.; Algás, R.; Marco, F.; Lledó, S.; Aliño, S.F. Nonviral Cancer Vaccines: From Free Antigens to Engineered Cells. In New Gene Therapy and Cancer Research; Gustafsson, W.B., Ed.; Nova Publishers: New York, NY, USA, 2008.
39. Serafini, P.; Carbley, R.; Noonan, K.A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64, 6337-6343.
40. Rodríguez-Lecompte, J.C.; Kruth, S.; Gyorffy, S.; Wan, Y.H.; Gauldie, J. Cell-based cancer gene therapy: Breaking tolerance or inducing autoimmunity. Anim. Health Res. Rev. 2004, 5, 227-234.
41. 5 minutes-averaged values of clearness index and relative optical air mass. Theor. Appl. Climatol. 2007, 90, 235-248.
42. Terando, A.M.; Faries, M.B.; Morton, D.L. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007, 25, B4-B16.
43. Zou, W. Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6, 295-307.
44. De Visser, K.; Eichten, A.; Coussens, L. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6, 24-37.
45. Serafini, P.; Borrello, I.; Bronte, V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16, 53-65.
46. Bossiotis, V.A.; Freeman, G.J.; Gribben, J.G.; Badler, L.M. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol. Rev. 1996, 15, 5-26.
47. Sperling, A.; Bluestone, J.A. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 1996, 153, 155-182.
48. Marengere, L.E.M.; Waterhouse, H.W.; Duncan, G.S.; Mittrucker, H.W.; Feng, G.S.; Mak, T.W. Regulation of T cell receptor signalling by tyrosine phosphatase SYP association with CTLA-4. Science 1996, 272, 1170-1173.
49. Onizuka, S.; Tawara, I.; Shimizu, J.; Sakaguchi, S.; Fujita, T.; Nakayama, E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999, 59, 3128-3133.
50. + Tcell dependent immune defense of B16 melanoma. Cancer Res. 2001, 61, 8643-8646.
51. + regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with IL-12 gene transfer. Exp. Dermatol. 2004, 13, 613-620.
52. Rech, A.J.; Vonderheide, R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. N. Y. Acad. Sci. 2009, 1174, 99-106.
53. Rech, A.J.; Mick, R.; Martin, S.; Recio, A.; Aqui, N.A.; Powell, D.J., Jr.; Colligon, T.A.; Trosko, J.A.; Leinbach, L.I.; Pletcher, C.H.; et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with inmunotherapy in cancer patients. Sci. Transl. Med. 2012, 4, 134ra62.
54. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002, 3, 135-142.
55. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271, 1734-1736.
56. Ascierto, P.A.; Marincola, F.M.; Ribas, A. Anti-CTLA4 monoclonal antibodies: The past and the future in clinical application. J. Transl. Med. 2011, 9, 196.
57. Attia, P.; Maker, A.V.; Haworth, L.R.; Rogers-Freezer, L.; Rosenberg, S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL2-ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 2005, 28, 582-592.
58. Dannull, J.; Su, Z.; Rizzieri, D.; Yang, B.K.; Coleman, D.; Yancey, D.; Zhang, A.; Dahm, P.; Chao, N.; Gilboa, E.; et al. Enhancement of vaccine-mediated antitumor immnunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115, 3623-3633.
59. Sharma, R.K.; Elpek, K.G.; Yolcu, E.S.; Schabowsky, R.H.; Zhao, H.; Bandura-Morgan, L.; Shirwan, H. Costimulation as a platform for the development of vaccines: A peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res. 2009, 69, 4319-4326.
60. Sharma, R.K.; Schabowsky, R.H.; Srivastava, A.K.; Elpek, K.G.; Madireddi, S.; Zhao, H.; Zhong, Z.; Miller, R.W.; Macleod, K.J.; Yolcu, E.S.; et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 2010, 70, 3945-3954.
61. + T regulatory cells by production of IFN-γ. PLoS One 2012, 7, e42459.
62. Murphy, K.A.; Lechner, M.G.; Popescu, F.E.; Bedi, J.; Decker, S.A.; Hu, P.; Erickson, J.R.; O'Sullivan, M.G.; Swier, L.; Salazar, A.M.; et al. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin. Cancer Res. 2012, 18, 4657-4668.
63. Horna, P.; Cuenca, A.; Cheng, F.; Brayer, J.; Wang, H.W.; Borrello, I.; Levitsky, H.; Sotomayor, E.M. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by Bcell lymphomas leading to antitumor immunity. Blood 2006, 107, 2871-2878.
64. Serafini, P.; Meckel, K.; Kelso, M.; Noonan, K.; Califano, J.; Koch, W.; Dolcetti, L.; Bronte, V.; Borrello, I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203, 2691-2702.
65. Frey, A.B. Myeloid supresor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 2006, 116, 2587-2590.
66. Filipazzi, P.; Valenti, R.; Huber, V.; Pilla, L.; Canese, P.; Iero, M.; Castelli, C.; Mariani, L.; Parmiani, G.; Rivoltini, L. Identification of a new subset of myeloid supresor cells in Peripherals blood of melanoma patients with modulation by a GM-CSF-based antitumor vaccine. J. Clin. Oncol. 2007, 25, 2546-2553.
67. Guillem, V.M.; Aliño, S.F. Transfection pathways of nonspecific and targeted PEI-polyplexes. Gene Ther. Mol. Biol. 2004, 8, 369-384.
68. Bordier, C. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 1981, 25, 1604-1607.